Gregory Bell

1.6k total citations
23 papers, 1.3k citations indexed

About

Gregory Bell is a scholar working on Nephrology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Gregory Bell has authored 23 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Nephrology, 6 papers in Immunology and 5 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Gregory Bell's work include Parathyroid Disorders and Treatments (6 papers), Immune Cell Function and Interaction (4 papers) and Magnesium in Health and Disease (3 papers). Gregory Bell is often cited by papers focused on Parathyroid Disorders and Treatments (6 papers), Immune Cell Function and Interaction (4 papers) and Magnesium in Health and Disease (3 papers). Gregory Bell collaborates with scholars based in United States, Australia and New Zealand. Gregory Bell's co-authors include Saling Huang, John B. Imboden, Mohammad Tabrizi, Sarah M. Nicoloro, Silvia Corvera, Michael Czech, Donald A. Mahler, Alison Burkart, Karen Mendelson and John Leszyk and has published in prestigious journals such as The Journal of Experimental Medicine, The Journal of Immunology and Molecular and Cellular Biology.

In The Last Decade

Gregory Bell

23 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gregory Bell United States 16 458 414 272 214 176 23 1.3k
Toshio Ogihara Japan 15 578 1.3× 311 0.8× 267 1.0× 82 0.4× 147 0.8× 40 1.6k
Kathrin Weyer Denmark 21 520 1.1× 155 0.4× 110 0.4× 253 1.2× 97 0.6× 47 1.5k
J Kao United States 12 760 1.7× 177 0.4× 323 1.2× 68 0.3× 113 0.6× 12 1.6k
Martha Konieczkowski United States 24 835 1.8× 221 0.5× 228 0.8× 541 2.5× 92 0.5× 41 1.8k
Craig F. Plato United States 17 915 2.0× 466 1.1× 88 0.3× 133 0.6× 179 1.0× 24 1.8k
Hiroki Takahashi Japan 20 486 1.1× 188 0.5× 247 0.9× 63 0.3× 153 0.9× 62 1.4k
Hisao Wakasaki Japan 16 740 1.6× 246 0.6× 93 0.3× 97 0.5× 94 0.5× 34 1.6k
Yumi Takiyama Japan 21 584 1.3× 168 0.4× 151 0.6× 174 0.8× 79 0.4× 48 1.4k
Linda A. Scharschmidt United States 14 257 0.6× 133 0.3× 236 0.9× 176 0.8× 88 0.5× 19 1.1k

Countries citing papers authored by Gregory Bell

Since Specialization
Citations

This map shows the geographic impact of Gregory Bell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory Bell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory Bell more than expected).

Fields of papers citing papers by Gregory Bell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregory Bell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory Bell. The network helps show where Gregory Bell may publish in the future.

Co-authorship network of co-authors of Gregory Bell

This figure shows the co-authorship network connecting the top 25 collaborators of Gregory Bell. A scholar is included among the top collaborators of Gregory Bell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregory Bell. Gregory Bell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bell, Gregory, Saling Huang, Kévin Martin, & Geoffrey A. Block. (2015). A randomized, double-blind, phase 2 study evaluating the safety and efficacy of AMG 416 for the treatment of secondary hyperparathyroidism in hemodialysis patients. Current Medical Research and Opinion. 31(5). 943–952. 34 indexed citations
2.
Bushinsky, David A., Geoffrey A. Block, Kévin Martin, et al.. (2015). Treatment of Secondary Hyperparathyroidism: Results of a Phase 2 Trial Evaluating an Intravenous Peptide Agonist of the Calcium-Sensing Receptor. American Journal of Nephrology. 42(5). 379–388. 16 indexed citations
3.
Grover, Suchi, Gregory Bell, Michael Lincoff, et al.. (2015). Utility of CMR Markers of Myocardial Injury in Predicting LV Functional Recovery: Results from PROTECTION AMI CMR Sub-study. Heart Lung and Circulation. 24(9). 891–897. 9 indexed citations
4.
Bagai, Akshay, Phillip J. Schulte, Christopher B. Granger, et al.. (2014). Prognostic implications of creatine kinase–MB measurements in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention. American Heart Journal. 168(4). 503–511.e2. 23 indexed citations
5.
6.
Walter, Sarah, Amos Baruch, James Tomlinson, et al.. (2013). Pharmacology of AMG 416 (Velcalcetide), a Novel Peptide Agonist of the Calcium-Sensing Receptor, for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients. Journal of Pharmacology and Experimental Therapeutics. 346(2). 229–240. 84 indexed citations
7.
Martin, Kévin, Saling Huang, Geoffrey A. Block, et al.. (2013). AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients. Kidney International. 85(1). 191–197. 53 indexed citations
8.
9.
Tabrizi, Mohammad, Bing Wang, Hong Lü, et al.. (2010). Population Pharmacokinetic Evaluation of a Fully Human IgG2 Monoclonal Antibody in Patients with Inflammatory Diseases. Inflammation & Allergy - Drug Targets. 9(4). 229–237. 13 indexed citations
10.
Mahler, Donald A., Saling Huang, Mohammad Tabrizi, & Gregory Bell. (2004). Efficacy and Safety of a Monoclonal Antibody Recognizing Interleukin-8 in COPD. CHEST Journal. 126(3). 926–934. 198 indexed citations
11.
Burkart, Alison, Gregory Bell, Karen Mendelson, et al.. (2003). Mitochondrial Biogenesis and Remodeling during Adipogenesis and in Response to the Insulin Sensitizer Rosiglitazone. Molecular and Cellular Biology. 23(3). 1085–1094. 401 indexed citations
12.
Bell, Gregory & Thomas J. Schnitzer. (2001). COX-2 inhibitors and other nonsteroidal anti-inflammatory drugs in the treatment of pain in the elderly. Clinics in Geriatric Medicine. 17(3). 489–502. 23 indexed citations
13.
Bell, Gregory, et al.. (1993). CD45-negative mutants of a rat natural killer cell line fail to lyse tumor target cells.. The Journal of Immunology. 151(7). 3646–3653. 18 indexed citations
14.
Weber, John R., et al.. (1992). Association of the tyrosine kinase LCK with phospholipase C-gamma 1 after stimulation of the T cell antigen receptor.. The Journal of Experimental Medicine. 176(2). 373–379. 119 indexed citations
15.
Bell, Gregory, William E. Seaman, Eréne C. Niemi, & John B. Imboden. (1992). The OX-44 molecule couples to signaling pathways and is associated with CD2 on rat T lymphocytes and a natural killer cell line.. The Journal of Experimental Medicine. 175(2). 527–536. 66 indexed citations
16.
Bell, Gregory, Joseph B. Bolen, & John B. Imboden. (1992). Association of Src-Like Protein Tyrosine Kinases with the CD2 Cell Surface Molecule in Rat T Lymphocytes and Natural Killer Cells. Molecular and Cellular Biology. 12(12). 5548–5554. 61 indexed citations
17.
Imboden, John B., Gregory Bell, & William E. Seaman. (1991). Characterization of signal-transducing molecules on natural killer cells. Biochemical Society Transactions. 19(2). 265–268. 1 indexed citations
18.
Bell, Gregory. (1987). Human Hybridomas: Diagnosis and Therapeutic Applications. Immunology. 61(4). 549. 1 indexed citations
19.
Hagamen, W. D., et al.. (1985). MEDCAT. ACM SIGAPL APL Quote Quad. 15(4). 308–314. 3 indexed citations
20.
Bell, Gregory & John Sinclair Lawrence Fowler. (1985). Red cell population distributions in healthy dogs. Research in Veterinary Science. 38(2). 220–225. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Toshio Ogihara Breakdown of academic impact, for papers by Kathrin Weyer Breakdown of academic impact, for papers by J Kao Breakdown of academic impact, for papers by Martha Konieczkowski Breakdown of academic impact, for papers by Craig F. Plato Breakdown of academic impact, for papers by Hiroki Takahashi Breakdown of academic impact, for papers by Hisao Wakasaki Breakdown of academic impact, for papers by Yumi Takiyama Breakdown of academic impact, for papers by Linda A. Scharschmidt
Rankless by CCL
2026